MCMedicalCodingSoftware
C86.51

C86.51Angioimmunoblastic T-cell lymphoma, in remission

Billable / specific codeICD-10-CM

C86.51 is a billable, specific ICD-10-CM code for angioimmunoblastic t-cell lymphoma, in remission. It is valid for submission on a claim.

Inclusion terms

Alternative wordings a physician may use in the chart for this same code.

  • Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD), in remission

Excludes1 inherited from the categories above C86.51

These are not written on C86.51, but they bind it: a note on a category applies to every code beneath it. Billing C86.51 with anything listed here is a denial.

Written on C86 Other specified types of T/NK-cell lymphoma

  • anaplastic large cell lymphoma, ALK negative (C84.7-)
  • anaplastic large cell lymphoma, ALK positive (C84.6-)
  • mature T/NK-cell lymphomas (C84.-)
  • other specified types of non-Hodgkin lymphoma (C85.8-)

Other codes that can never be billed with C86.51

These codes carry an Excludes1 note pointing at C86.51. The conflict binds both ways, but ICD-10-CM only writes it down on one side — so you would not find this by reading C86.51 alone.

  • C85Other specified and unspecified types of non-Hodgkin lymphoma

Risk adjustment

C86.51 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:

  • HCC 19 Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers1.798 RAF

Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.

Medicare coverage

C86.51 is named in 35 Medicare coverage policies 35 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.

  • A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
  • A52479Oral Anticancer Drugs - Policy Article
  • A52479Oral Anticancer Drugs - Policy Article
  • A52479Oral Anticancer Drugs - Policy Article

Code history

What changed, and when. Derived by diffing consecutive CMS release files — which matters when you are defending a code assigned under an earlier edition.

  • addedFY2024-FY2026

    Angioimmunoblastic T-cell lymphoma, in remission

Related codes at this level

Codes that share C86.5. If C86.51 is not quite right, the correct code is usually one of these.

Questions about C86.51

Is C86.51 a billable ICD-10-CM code?
Yes. C86.51 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
Where does C86.51 sit in the tabular list?
Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).
What cannot be coded together with C86.51?
C86.51 carries Excludes1 notes, which means the conditions they list can never be coded together with it on the same encounter. Some are written on the categories above C86.51 (C86) and apply to it just the same.
ICD-10-CMFY2026-Apr· effective April 1, 2026

Loaded directly from the CMS/NCHS ICD-10-CM public-domain release — see data sources and our editorial policy. If this page disagrees with the CMS tabular list, this page is wrong. Reference information for professional coders; not medical or billing advice.